Skip to main content
Medical information Clinical review pending

Genetic Testing

Chr 15q11 Gene Angelman Syndrome Genetic Test

This genetic test identifies anomalies in the 15q11 chromosome region associated with Angelman Syndrome, a neurological disorder. It uses Next-Generation Sequencing (NGS) to analyze DNA.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube), extracted DNA, or one drop of blood on an FTA card. Confirm specific requirements with the laboratory before booking.
Results
Approximately 3 to 4 weeks. Confirm exact turnaround time with the laboratory before booking.
Preparation
A clinical history of the patient is recommended. A genetic counseling session to discuss family history and create a pedigree chart may be beneficial prior to testing. No fasting is required.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Chr 15q11 Gene Angelman Syndrome Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Individuals presenting with symptoms suggestive of Angelman Syndrome
  • ✓Developmental delays
  • ✓Severe intellectual disability
  • ✓Speech impairment
  • ✓Movement or balance disorders
  • ✓Seizures
  • ✓Family history of Angelman Syndrome or related neurological disorders
  • ✓Referral by a neurologist or geneticist
02

In plain language

What this test helps you understand

This test aids in the diagnosis of Angelman Syndrome by identifying specific genetic changes in the 15q11 chromosome region. Accurate diagnosis allows for appropriate medical management, access to support services, and genetic counseling for the individual and their family.
The Chr 15q11 Gene Angelman Syndrome NGS Genetic DNA Test is a specialized genetic analysis designed to detect specific changes in the 15q11 chromosome region linked to Angelman Syndrome. This is a complex neurological disorder affecting development. Early and accurate diagnosis is important for managing the condition and accessing appropriate support.

This test utilizes advanced Next-Generation Sequencing (NGS) technology to examine the patient's genetic material. It looks for deletions, mutations, or other alterations in the 15q11 chromosomal area that are known causes of Angelman Syndrome.

This test is typically recommended for individuals exhibiting symptoms suggestive of Angelman Syndrome. These symptoms can include developmental delays, significant speech impairment, severe intellectual disability, difficulties with movement and balance, and seizures. It may also be considered for individuals with a family history of neurological disorders or those referred by a healthcare professional, such as a neurologist.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationA clinical history of the patient is recommended. A genetic counseling session to discuss family history and create a pedigree chart may be beneficial prior to testing. No fasting is required.
SampleBlood sample (EDTA tube), extracted DNA, or one drop of blood on an FTA card. Confirm specific requirements with the laboratory before booking.
MethodologyNext-Generation Sequencing (NGS) analysis of the 15q11 chromosomal region.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test specifically analyzes the 15q11 region for common causes of Angelman Syndrome. It may not detect all possible genetic causes. A negative result does not completely rule out the condition. Results should be interpreted by a qualified professional in the context of the patient's clinical presentation.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

Angelman Syndrome is a genetic disorder that primarily affects the nervous system. It causes severe developmental delays, intellectual disability, speech impairment, and movement or balance disorders.
This test is recommended for individuals showing symptoms of Angelman Syndrome, such as developmental delays, speech problems, seizures, or movement difficulties. It may also be considered if there is a family history of the condition.
The test involves analyzing a sample of the patient's DNA, typically obtained from a blood sample, extracted DNA, or a blood spot on an FTA card. The laboratory uses Next-Generation Sequencing (NGS) technology.
A positive result indicates the presence of genetic changes associated with Angelman Syndrome. A negative result does not entirely rule out the condition. Results require interpretation by a healthcare professional, often in consultation with a genetic counselor.
The turnaround time is typically around 3 to 4 weeks. Please confirm the current turnaround time with the laboratory before booking.
The price for this test is KSh 40,000. Confirm current pricing and any available discounts with the laboratory.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp